AMSは北大発認定スタートアップ企業です
AMS Secures $1.0M in Pre-Series A Funding Round,
Bringing Total Fundraising to $2.2M
June 3 , 2025
On May 30, 2025, AMS successfully raised $1.0M in its Pre-Series A funding round through a third-party allocation of shares. With this round, our total fundraising to date reaches $2.2M.
The investment was led by existing investor MIRAISOZO INVESTMENTS and welcomed new investor Vision Incubate. These funds will accelerate our efforts to expand into new markets and advance our pipeline of innovative solutions in nuclear medicine.
The investment was led by existing investor MIRAISOZO INVESTMENTS and welcomed new investor Vision Incubate. These funds will accelerate our efforts to expand into new markets and advance our pipeline of innovative solutions in nuclear medicine.
About AMS
AMS is a venture-backed nuclear medicine startup redefining patient access to life-saving treatments.
Drawing on decontamination technology currently in use at Fukushima (the site of Japan’s nuclear accident), AMS has developed the world's first filtration system for rapidly and safely removing radioisotopes from medical biowaste. Already deployed at leading hospitals across Japan, this system eliminates regulatory and infrastructure barriers to nuclear medicine therapies, enabling hospitals to optimize patient flow and enhance staff safety.
We are actively exploring market expansion opportunities in the U.S. and Germany through active discussions with key industry stakeholders.
AMS’s team combines deep expertise in nuclear science and medicine. Building on decades of leadership experience in the highly regulated power utility and healthcare sectors, we are uniquely positioned to scale our proprietary technology and maximize access to nuclear medicine worldwide. Our pipeline also includes novel theranostics radiopharmaceuticals based on this same platform.
At AMS, we are focused on delivering practical and transformative solutions that further advance the fast-evolving field of nuclear medicine.
For more details about our mission and technology, please visit our website: AMS Official Website
Drawing on decontamination technology currently in use at Fukushima (the site of Japan’s nuclear accident), AMS has developed the world's first filtration system for rapidly and safely removing radioisotopes from medical biowaste. Already deployed at leading hospitals across Japan, this system eliminates regulatory and infrastructure barriers to nuclear medicine therapies, enabling hospitals to optimize patient flow and enhance staff safety.
We are actively exploring market expansion opportunities in the U.S. and Germany through active discussions with key industry stakeholders.
AMS’s team combines deep expertise in nuclear science and medicine. Building on decades of leadership experience in the highly regulated power utility and healthcare sectors, we are uniquely positioned to scale our proprietary technology and maximize access to nuclear medicine worldwide. Our pipeline also includes novel theranostics radiopharmaceuticals based on this same platform.
At AMS, we are focused on delivering practical and transformative solutions that further advance the fast-evolving field of nuclear medicine.
For more details about our mission and technology, please visit our website: AMS Official Website